Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A compound directed against S6K1 hampers fat mass expansion and mitigates diet-induced hepatosteatosis

ABSTRACT: A compound directed against S6K1 hampers fat mass expansion and mitigates diet-induced hepatosteatosis

PROVIDER: PRJNA794149 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

A compound directed against S6K1 hampers fat mass expansion and mitigates diet-induced hepatosteatosis

Project description:Imbalanced mTORC1-S6K1 engages signalling cascades related to obesity and fatty liver. Here, we set up to assess the therapeutic blockage of the ribosomal protein S6 kinase 1 (S6K1) in diet-induced obese (DIO) mice challenged with LY2584702 (LY) tosylate, a specific oral S6K1 inhibitor initially developed for the treatment of solid tumours. To characterize the ability of LY in counteracting obesity and diet-induced disturbances, DIO male mice were challenged every 12 h by oral gavage with LY in treatments lasting 12 and 4 weeks. We show that diminished S6K1 activity in mice treated with LY hampers fat mass expansion and ameliorates dyslipidaemia and hepatic steatosis, while modifying transcriptome-wide gene expression programs relevant for adipose and liver performance. Accordingly, impaired mTORC1 signalling in fat (decreased) and liver (increased) co-segregated with defective epithelial-mesenchymal transition, being prominent a decreased expression of Cd36 (coding for a fatty acid translocase) and Lgals1 (Galectin 1) in both tissues. All these factors combined align with reduced adipocyte size and improved lipidomic signatures, while hypertriglyceridemia and hepatic steatosis were improved in treatments of 12 and 4 weeks. This study provides new insights into the therapeutic intervention of S6K1 signalling, and opens a promising avenue for prevalent metabolic diseases.

2022-08-01 | GSE193028 | GEO

A compound directed against S6K1 hampers fat mass expansion and mitigates diet-induced hepatosteatosis.

Project description:The ribosomal protein S6 kinase 1 (S6K1) is a relevant effector downstream of the mammalian target of rapamycin complex 1 (mTORC1), best known for its role in the control of lipid homeostasis. Consistent with this, mice lacking the S6k1 gene have a defect in their ability to induce the commitment of fat precursor cells to the adipogenic lineage, which contributes to a significant reduction of fat mass. Here, we assess the therapeutic blockage of S6K1 in diet-induced obese mice challenged with LY2584702 tosylate, a specific oral S6K1 inhibitor initially developed for the treatment of solid tumors. We show that diminished S6K1 activity hampers fat mass expansion and ameliorates dyslipidemia and hepatic steatosis, while modifying transcriptome-wide gene expression programs relevant for adipose and liver function. Accordingly, decreased mTORC1 signaling in fat (but increased in the liver) segregated with defective epithelial-mesenchymal transition and the impaired expression of Cd36 (coding for a fatty acid translocase) and Lgals1 (Galectin 1) in both tissues. All these factors combined align with reduced adipocyte size and improved lipidomic signatures in the liver, while hepatic steatosis and hypertriglyceridemia were improved in treatments lasting either 3 months or 6 weeks.

| S-EPMC9431684 | biostudies-literature

oral insulin mimetics (OIM): compound-immobilized beads-mass spectrometry

Project description:L6-G4 cell lysate were sujected to compound-immobilized beads followed by mass spectrometry

2020-07-16 | PXD014623 | JPOST Repository

Exercise Mitigates Skeletal Muscle Epigenetic Aging

Project description:Exercise late in life mitigates skeletal muscle epigenetic aging, providing evidence that physical activity is a "fountain of youth".

2021-12-31 | GSE175410 | GEO

Liver proteomics of the HMDP - Hepatosteatosis underlies several diseases including type 2 diabetes, cardiovascular disease and liver disease

Project description:Hepatosteatosis underlies several diseases including type 2 diabetes, cardiovascular disease and liver disease. Unfortunately, our understanding of the contributing pathways that initiate and advance hepatosteatosis to subsequent complications is still poorly understood. Here, we take advantage of recent developments in “omics” technologies to perform high resolution proteomics (>5000 proteins) and quantitative lipidomics (>300 lipids) on livers from 107 genetically diverse inbred mouse strains from the hybrid mouse diversity panel. Integration of these data allowed us to define novel regulators of lipid metabolism in the liver.

2019-11-01 | PXD007281 | Pride

Dystrophin deficiency hampers cell state transitions during somite development

Project description:Dystrophin deficiency hampers cell state transitions during somite development

| PRJNA976739 | ENA

CN133 hampers tumor growth in patient-derived pediatric ependymoma models

Project description:CN133 hampers tumor growth in patient-derived pediatric ependymoma models

| PRJNA578748 | ENA

The alarmin S100A9 hampers retroviral infection by limiting reverse transcription

Project description:The alarmin S100A9 hampers retroviral infection by limiting reverse transcription

| PRJNA727578 | ENA

Mass culture of rotifer

Project description:Mass culture of rotifer Metagenome